What Is Low-Grade Dysplasia in the Colon?

Low-grade dysplasia in the colon refers to mildly abnormal cell growth in the lining of the large intestine, almost always discovered when a pathologist examines tissue removed during a colonoscopy. It is not cancer, but it sits on the spectrum between normal tissue and malignancy, which is why it gets so much clinical attention. The term shows up in two very different situations: inside ordinary polyps that most adults develop with age, and in the inflamed colon lining of people with inflammatory bowel disease. How much it matters depends heavily on which of those contexts applies to you.

What a Pathologist Sees Under the Microscope

After a polyp or biopsy sample is removed during colonoscopy, it goes to a pathology lab where it is sliced thin, stained, and examined under a microscope. Dysplasia is diagnosed based on a combination of changes in cell appearance and in the architecture of the tiny tube-shaped glands (called crypts) that line the colon wall.¹ In low-grade dysplasia, the nuclei of the cells look darker, more crowded, and slightly elongated compared to normal tissue, but they still mostly stay in the lower portion of the cell. The gland structure may be mildly distorted but hasn’t gone haywire. When those changes become more severe, with nuclei losing their orderly arrangement and glands taking on a chaotic branching pattern, the diagnosis shifts to high-grade dysplasia, which is a much more immediate concern.

The distinction between low and high grade is important because it drives clinical decisions, but it is not always a clean line. More on that diagnostic gray zone shortly.

Sporadic Polyps With Low-Grade Dysplasia

The most common scenario by far is a routine colonoscopy turning up one or more small polyps that, under the microscope, show the features of a tubular adenoma with low-grade dysplasia. This is an extremely common finding. Most adenomatous polyps, the kind considered precancerous, are low-grade. The vast majority of these will never become cancer, especially if they are small and completely removed.

Size matters quite a bit here. A study tracking patients after polypectomy found that among people whose largest removed adenoma was 1 to 5 millimeters, about 4% developed an advanced lesion during roughly three years of follow-up. For those whose largest adenoma measured 6 to 9 millimeters, the rate was closer to 10%, with a roughly threefold higher hazard of advanced neoplasia.² “Advanced neoplasia” in this context means either high-grade dysplasia or actual cancer, so the absolute risk from tiny low-grade polyps is genuinely low, though not zero.

The polyp’s internal structure also plays a role. Tubular adenomas, which have a fairly regular gland pattern, are the most common and generally the least worrisome. Villous adenomas, which have finger-like projections, tend to show more abnormal cell division even at the low-grade dysplasia stage.³ Many polyps are a mix of the two patterns, called tubulovillous adenomas.

Low-Grade Dysplasia in Inflammatory Bowel Disease

Finding low-grade dysplasia in someone with longstanding ulcerative colitis or Crohn’s colitis is a very different clinical situation. Chronic inflammation batters the colon lining for years, and the resulting dysplasia doesn’t always grow as a tidy polyp; it can appear as a flat, barely visible patch of tissue that is hard to spot even with a good endoscope. This flat low-grade dysplasia in IBD carries a meaningfully higher cancer risk than a typical sporadic polyp.

A meta-analysis pooling data from multiple surveillance studies found that when low-grade dysplasia is detected in ulcerative colitis, the risk of eventually developing colorectal cancer is about ninefold higher than in patients without dysplasia, and the risk of any advanced lesion (high-grade dysplasia or cancer) is roughly twelvefold higher.⁴ An older but frequently cited single-center study reported that flat low-grade dysplasia in ulcerative colitis progressed to advanced neoplasia at a rate of 53% within five years.⁵ That number sounds alarming, and it was influential in pushing many gastroenterologists toward recommending colectomy for any flat low-grade dysplasia in IBD.

More recent data paints a somewhat less dire picture, at least for patients who stay in close surveillance. A systematic review and meta-analysis focused specifically on flat low-grade dysplasia in IBD found the pooled incidence of colorectal cancer was about 0.5 per 100 patient-years, and the incidence of any advanced neoplasia was roughly 1.7 per 100 patient-years.⁶ That is still elevated compared to the general population, but it suggests that with modern endoscopy and careful follow-up, the progression rate is lower than that older 53% figure implied. The difference likely reflects improvements in detection and management over the past two decades.

Why Pathologists Sometimes Disagree on the Diagnosis

One of the most underappreciated problems with low-grade dysplasia is that pathologists don’t always agree on what it is. The diagnosis lives in a murky zone between reactive changes (where inflamed tissue looks abnormal but isn’t truly precancerous) and genuine early neoplasia. Studies measuring agreement among pathologists paint a surprisingly sobering picture.

In one study, four pathologists reviewing the same set of ulcerative colitis biopsies agreed only “fairly” overall, with the weakest agreement occurring in the low-grade dysplasia and “indefinite for dysplasia” categories. The agreement statistic for low-grade dysplasia was 0.36, compared to 0.54 for high-grade dysplasia.⁷ A separate study comparing specialist gastrointestinal pathologists to general pathologists found that the specialists were no better at grading dysplasia. Total concordance among all 13 pathologists occurred in fewer than 8% of slides.⁸

This variability is one reason why guidelines generally recommend that a diagnosis of dysplasia in IBD be confirmed by a second, independent pathologist before making big treatment decisions. It is also why the diagnostic category “indefinite for dysplasia” exists: rather than forcing a binary call, pathologists can flag tissue where they are genuinely unsure whether the changes represent true dysplasia or just inflammation-related atypia.⁹ If your biopsy report says “indefinite,” it doesn’t mean the pathologist was careless; it means the tissue fell in a gray zone that the grading system was designed to acknowledge honestly.

How Low-Grade Dysplasia Is Removed

For sporadic polyps, the treatment is straightforward: remove the polyp completely during the colonoscopy. Current European guidelines recommend cold snare polypectomy, with a small margin of normal tissue around the polyp, for lesions up to 9 millimeters. For polyps 10 to 19 millimeters, hot snare polypectomy (which uses electrical current) is preferred. Larger lesions of 20 millimeters or more call for endoscopic mucosal resection, a technique that lifts the tissue with a fluid injection before snaring it off.¹⁰ Biopsy forceps alone are discouraged because they leave behind too much tissue too often.¹¹

For IBD-related dysplasia, the situation is more nuanced. If the dysplastic area is a visible, well-defined lesion that can be completely removed endoscopically, most current guidelines support endoscopic resection followed by close surveillance, rather than jumping straight to colectomy. But if the dysplasia is invisible, multifocal (appearing in several spots), or the endoscopist can’t confidently clear the margins, surgery to remove part or all of the colon remains on the table. This is where the conversation between gastroenterologist, surgeon, and patient gets highly individualized.

Surveillance After Removal

Once a low-grade adenoma is removed, the question becomes when to come back for another colonoscopy. Guidelines vary by region and by risk profile. For patients with one to four small adenomas under 10 millimeters showing low-grade dysplasia, European guidelines generally recommend returning to routine screening rather than scheduling a dedicated surveillance colonoscopy. American guidelines tend to be a bit more aggressive, recommending follow-up colonoscopy at 7 to 10 years for one or two small tubular adenomas, and at 3 to 5 years if three or four are found.¹²

For IBD patients with dysplasia, surveillance is much tighter, often involving colonoscopy every one to two years with enhanced imaging techniques. Chromoendoscopy, which uses dye sprayed onto the colon surface to highlight subtle flat lesions, detects dysplasia more effectively than standard white-light colonoscopy. A randomized study comparing methylene blue chromoendoscopy to virtual chromoendoscopy found that the dye-based approach picked up dysplasia in 12% of patients versus 8% with the virtual technique, with the dye method proving better at spotting flat lesions and those located in the upper part of the colon.¹³

A cost-effectiveness analysis found that both low-intensity and high-intensity surveillance after adenoma removal provided good value compared to simply resuming routine screening, suggesting the follow-up colonoscopies are worth the investment.¹⁴

Can Low-Grade Dysplasia Regress on Its Own?

This is something many patients wonder about, and the short answer is: sometimes, particularly in the IBD setting. A prospective study of ulcerative colitis patients with low-grade dysplasia found that roughly 80% either maintained their low-grade status or were downgraded to “indefinite” or negative for dysplasia over time. Among those who did not progress, more than half had biopsies that were negative for dysplasia by the end of follow-up.¹⁵

This doesn’t mean dysplasia can be safely ignored. The trouble is that you can’t predict which patients will regress and which will progress. And “regression” on biopsy could sometimes reflect sampling error, where the dysplastic area was simply missed on the next colonoscopy rather than truly disappearing. Still, the finding does support a watchful approach with close surveillance rather than immediate surgery for many IBD patients with isolated low-grade dysplasia.

The Serrated Pathway and Why It Complicates Things

Not all precancerous colon lesions follow the classic adenoma-to-cancer route. There is a separate pathway involving sessile serrated lesions, which are flat polyps with a distinctive sawtooth pattern under the microscope. These lesions are common, tend to appear in the right side of the colon, and for a long time were dismissed as harmless. But when a sessile serrated lesion develops dysplasia, even low-grade dysplasia, the transition to cancer can be faster than the classic pathway.¹⁶

Sessile serrated lesions with dysplasia tend to appear in older patients, are more common in women, and cluster in the proximal colon, the part farthest from the rectum and hardest to reach during colonoscopy.¹⁷ The practical takeaway is that not all “low-grade dysplasia” findings carry the same weight. A small tubular adenoma with low-grade dysplasia in the sigmoid colon has a very different risk profile from a sessile serrated lesion with low-grade dysplasia in the cecum, even though both technically carry the “low-grade” label.

Non-Conventional Dysplasia Patterns in IBD

Researchers have identified several subtypes of dysplasia in IBD that don’t look like a classic adenoma. These non-conventional patterns include variants with unusual cell features, such as increased Paneth cell differentiation, goblet cell deficiency, or a hypermucinous appearance. In a large study classifying IBD-related dysplastic lesions, the conventional types (tubular adenoma-like and tubulovillous/villous adenoma-like) still predominated, but non-conventional patterns made up a meaningful minority.¹⁸ The concern is that these non-conventional subtypes appear to carry a higher risk of being associated with advanced neoplasia and chromosomal instability. They’re also less familiar to pathologists, making them easier to miss or misclassify.

Molecular Clues That Help Predict Risk

One of the frustrations of low-grade dysplasia is that the microscopic appearance alone doesn’t reliably predict which lesions will progress. Researchers are increasingly looking at molecular markers for help. The gene TP53, which encodes a tumor-suppressing protein called p53, is one of the most studied. Abnormal p53 staining on tissue samples has been shown to predict progression to more advanced disease, and it correlates strongly with actual TP53 mutations.¹⁹ While much of this research has been conducted in the esophagus (specifically Barrett’s esophagus), the principle extends to colorectal dysplasia. P53 staining is increasingly used as a practical add-on to help pathologists decide whether a borderline biopsy represents true dysplasia or reactive change.²⁰

In the IBD setting, the molecular landscape of low-grade dysplasia differs depending on whether the lesion behaves like a sporadic adenoma or is truly colitis-driven. Lesions arising in non-inflamed areas tend to carry APC gene mutations, the hallmark of the classic polyp-to-cancer pathway. In contrast, dysplastic lesions associated with active colitis or with synchronous cancer are more likely to harbor TP53 mutations and may show different patterns of genetic instability.²¹ Microsatellite instability, a type of DNA repair defect, is also relatively common even in early IBD-associated neoplasia.²²

Lifestyle Factors and Polyp Risk

While you can’t control every variable, several lifestyle factors are consistently linked to the risk of developing adenomatous polyps in the first place. A large study found six modifiable risk factors independently associated with polyp development: smoking, obesity, not using anti-inflammatory medications regularly, high red meat intake, low fiber intake, and low calcium intake. People who stacked five or six of these risk factors had roughly triple the odds of having adenomas compared to those with none or one.²³

For the serrated polyp pathway specifically, smoking and high red meat consumption stand out as particularly strong associations. Regular use of anti-inflammatory medications was linked to about a 40% reduction in serrated polyp risk.²⁴ Abdominal obesity, high body mass index, and metabolic syndrome have also been associated with increased polyp risk across subtypes.²⁵

That said, the evidence on dietary interventions to prevent polyp recurrence is less encouraging than you might expect. A large randomized trial testing a low-fat, high-fiber diet found no reduction in adenoma recurrence over a four-year follow-up period; about 40% of participants in both the diet group and the control group developed recurrent adenomas.²⁶ This doesn’t mean diet is irrelevant to colon cancer risk over a lifetime, but it does mean that once you already have adenomas, changing your diet alone is unlikely to prevent new ones from forming.

Artificial Intelligence During Colonoscopy

One of the more promising recent developments is the use of AI-assisted tools during colonoscopy to help endoscopists classify polyps in real time. A deep learning model analyzing standard colonoscopy video was able to differentiate tiny adenomas from non-neoplastic hyperplastic polyps with about 94% accuracy and 98% sensitivity.²⁷ A larger real-world trial found that AI-assisted diagnosis performed comparably to standard visual inspection in terms of sensitivity and specificity, but the AI system made its calls with high confidence far more often, about 93% of the time versus 74% for human assessment alone.²⁸

These tools aren’t replacing pathologists yet, but they could eventually allow endoscopists to make confident enough real-time judgments about tiny polyps to skip sending them for histology, a strategy sometimes called “diagnose and leave” for obviously benign-looking lesions. For now, the tissue still goes to the lab, and the pathologist still makes the call on dysplasia grade. But the technology is getting closer to changing that workflow, particularly for the smallest and most common polyps.